leflunomide has been researched along with Complication, Postoperative in 10 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 7.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Leflunomide was selected as a last resort to avoid the nephrotoxicity of cidofovir." | 5.34 | Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. ( Abdelhalim, A; Almyroudis, NG; Battiwalla, M; Becker, J; Elefante, A; McCarthy, A; McCarthy, PL; Paplham, P; Segal, BH; Smith, P, 2007) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 3.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Leflunomide treatment for CMV disease in renal transplant recipients is effective, simple, and economical." | 2.71 | A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. ( Balakrishnan, N; Chandy, S; Chandy, SJ; Fleming, DH; Jacob, CK; John, GT; Kirubakaran, MG; Krishnamurthy, K; Manivannan, J; Peter, S, 2005) |
| " The dosage and time of therapy need to be explored in the future; additional studies of large samples are needed." | 1.42 | BK Virus-Associated Nephropathy with Plasma Cell-Rich Infiltrates Treated by Bortezomib-Based Regimen. ( Chen, JS; Cheng, DR; Ji, SM; Li, X; Liu, ZH; Wen, JQ; Wu, D; Xie, KN; Zhang, MC, 2015) |
| "Leflunomide was selected as a last resort to avoid the nephrotoxicity of cidofovir." | 1.34 | Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. ( Abdelhalim, A; Almyroudis, NG; Battiwalla, M; Becker, J; Elefante, A; McCarthy, A; McCarthy, PL; Paplham, P; Segal, BH; Smith, P, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Echenique, IA | 1 |
| Beltran, D | 1 |
| Ramirez-Ruiz, L | 1 |
| Najafian, N | 1 |
| Agrawal, N | 1 |
| Velázquez Benito, A | 1 |
| Bellosta Diago, E | 1 |
| Santos Lasaosa, S | 1 |
| Pascual Millán, LF | 1 |
| Wu, D | 1 |
| Zhang, MC | 1 |
| Chen, JS | 1 |
| Li, X | 1 |
| Cheng, DR | 1 |
| Xie, KN | 1 |
| Ji, SM | 1 |
| Liu, ZH | 1 |
| Wen, JQ | 1 |
| Jung, YH | 1 |
| Moon, KC | 1 |
| Ha, JW | 1 |
| Kim, SJ | 1 |
| Ha, IS | 1 |
| Cheong, HI | 1 |
| Kang, HG | 1 |
| John, GT | 1 |
| Manivannan, J | 1 |
| Chandy, S | 1 |
| Peter, S | 1 |
| Fleming, DH | 1 |
| Chandy, SJ | 1 |
| Balakrishnan, N | 1 |
| Krishnamurthy, K | 1 |
| Kirubakaran, MG | 1 |
| Jacob, CK | 1 |
| Josephson, MA | 1 |
| Javaid, B | 1 |
| Kadambi, PV | 1 |
| Meehan, SM | 1 |
| Williams, JW | 1 |
| Fuerst, M | 1 |
| Möhl, H | 1 |
| Baumgärtel, K | 1 |
| Rüther, W | 1 |
| Duclos, AJ | 1 |
| Krishnamurthi, V | 1 |
| Lard, M | 1 |
| Poggio, E | 1 |
| Kleeman, M | 1 |
| Winans, C | 1 |
| Fatica, R | 1 |
| Nurko, S | 1 |
| Battiwalla, M | 1 |
| Paplham, P | 1 |
| Almyroudis, NG | 1 |
| McCarthy, A | 1 |
| Abdelhalim, A | 1 |
| Elefante, A | 1 |
| Smith, P | 1 |
| Becker, J | 1 |
| McCarthy, PL | 1 |
| Segal, BH | 1 |
| Gregory, CR | 1 |
3 reviews available for leflunomide and Complication, Postoperative
| Article | Year |
|---|---|
Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation.
Topics: Antiviral Agents; BK Virus; Child; Female; Humans; Isoxazoles; Kidney Diseases; Kidney Transplantati | 2013 |
Leflunomide in solid organ transplantation and polyoma virus infection.
Topics: Antiviral Agents; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Organ Transplantation; | 2006 |
Immunosuppressive approaches to the prevention of graft vascular disease.
Topics: Coronary Disease; Cyclosporine; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase I | 1998 |
1 trial available for leflunomide and Complication, Postoperative
| Article | Year |
|---|---|
A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Humans; Isoxazoles; Kidney Transplantat | 2005 |
6 other studies available for leflunomide and Complication, Postoperative
| Article | Year |
|---|---|
Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report.
Topics: Aged; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Dose-Respo | 2017 |
[Acute sensory-motor axonal neuropathy (Guillain-Barre syndrome) following vertebroplasty].
Topics: Accidental Falls; Arthritis, Rheumatoid; Female; Guillain-Barre Syndrome; Humans; Immunocompromised | 2014 |
BK Virus-Associated Nephropathy with Plasma Cell-Rich Infiltrates Treated by Bortezomib-Based Regimen.
Topics: Adult; Antineoplastic Agents; BK Virus; Bortezomib; Female; Humans; Isoxazoles; Kidney Diseases; Kid | 2015 |
Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Combined Modality Thera | 2006 |
Prevalence and clinical course of BK virus nephropathy in pancreas after kidney transplant patients.
Topics: Antiviral Agents; BK Virus; Drug Therapy, Combination; Humans; Immunosuppression Therapy; Isoxazoles | 2006 |
Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Therapy, Co | 2007 |